Abstract
Background
Sacituzumab govitecan (SG) has shown clinical activity in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+/HER2− MBC), although evidence remains limited and heterogeneous. We performed a systematic review and meta-analysis to evaluate its efficacy and safety.
Methods
Studies assessing SG in HR+/HER2− MBC were systematically identified. Outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Random-effects models were used for pooled analyses.
Results
Twelve studies including 2431 patients (5 clinical trials, 7 real-world studies) were analyzed. The pooled ORR was 23% (95% CI, 17%–31%) and DCR was 68% (95% CI, 52%–80%). Median PFS and OS were 5.35 months (95% CI, 3.96–7.22) and 12.66 months (95% CI, 10.68–15.01), respectively. No significant differences in ORR were observed according to prior cyclin-dependent kinase 4/6 (CDK4/6) inhibitor exposure, number of prior treatment lines, or study design. Grade ≥3 neutropenia, febrile neutropenia, and diarrhea occurred in 46%, 5%, and 8% of patients, respectively.
Conclusions
SG demonstrates clinically meaningful antitumor activity in heavily pretreated patients with HR+/HER2− MBC. No statistically significant differences in ORR were detected according to prior CDK4/6 inhibitor exposure, number of prior treatment lines, or study design; however, these findings should be interpreted cautiously given the limited number of studies and substantial heterogeneity. Within a continuously evolving treatment landscape, further prospective studies are warranted to better define the optimal positioning of SG.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
